What are the anticoagulation options for intermittent hemodialysis?
- 5 July 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Nephrology
- Vol. 7 (9), 499-508
- https://doi.org/10.1038/nrneph.2011.88
Abstract
Prevention of clotting in the extracorporeal circuit was one of the major hurdles that had to be overcome to enable the expansion of routine outpatient hemodialysis to free-standing satellite centers and the home. Unfractionated heparin, the anticoagulant of choice for many years, is now being replaced by low-molecular-weight heparins (LMWHs) in an expanding number of countries. This trend is attributable to the ease and convenience of the administration of LMWHs coupled with their reliability and predictability of dosing. However, the choice of which LMWH to use depends on the duration and frequency of the dialysis sessions. For patients who are allergic to heparin or have heparin-induced thrombocytopenia, alternative anticoagulants--the direct thrombin inhibitors and heparinoids--are now available. These agents either have short half-lives (and therefore need to be delivered by infusions), or prolonged half-lives, which allows simple bolus administration, but increases the risk of drug accumulation, overdosage and hemorrhage. In patients at risk of bleeding, regional anticoagulants enable anticoagulation to be limited to the extracorporeal circuit. Prostanoids and nafamostat mesilate are expensive regional anticoagulants, and citrate infusions add complexity to the procedure. A citrate-based dialyzate has now been introduced that might enable heparin-free dialysis or reduce systemic anticoagulant requirements.Keywords
This publication has 94 references indexed in Scilit:
- Utility of citrate dialysate in management of acute kidney injury in childrenHemodialysis International, 2010
- Increased Efficiency of Hemodialysis with Citrate DialysateClinical Journal of the American Society of Nephrology, 2009
- Review article: Low‐molecular‐weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatmentsNephrology, 2009
- The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysisHemodialysis International, 2009
- Heparin-induced thrombocytopenia: An uncommon but serious complication of heparin use in renal replacement therapyHemodialysis International, 2006
- The Acute Dialysis Quality Initiative—Part VI: Access and anticoagulation in CRRTAdvances in Renal Replacement Therapy, 2002
- Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin®)Intensive Care Medicine, 1991
- Controlled Study of Heparin versus Epoprostenol Sodium (Prostacyclin) as the Sole Anticoagulant for Chronic HemodialysisBlood Purification, 1991
- Regional Citrate Anticoagulation for Hemodialysis in the Patient at High Risk for BleedingThe New England Journal of Medicine, 1983
- Hemodialysis Using Prostacyclin Instead of Heparin as the Sole Antithrombotic AgentThe New England Journal of Medicine, 1981